Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms
- 18 July 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 12 (10) , 1211-1224
Abstract
Significant advances in antiretroviral (ARV) therapy have transformed HIV into a chronic manageable disease. Co-morbidities associated with aging, such as benign prostatic hyperplasia (BPH), are becoming increasingly prevalent in the HIV-infected population. The pharmacological treatment of BPH involves medications mainly metabolized by CYP 450 enzymes, while many ARVs have inducing or inhibiting effects on the CYP 450 system. Consequently, there is potential for significant pharmacokinetic (PK) interactions between these two classes of medications. This article reviews the pharmacology and metabolism of selected BPH drug therapies and ARVs, in addition to highlighting potential interactions between these two drug categories. The authors also present PK evidence of interactions from available clinical trials, product monographs and international conference abstracts. Potentially significant drug interactions are summarized and strategies for management are discussed. Drugs most likely to interact with BPH medications include protease inhibitors, the non-nucleoside reverse transcriptase inhibitors efavirenz, nevirapine, etravirine, and the cobicistat-boosted integrase inhibitor elvitegravir. Clinically significant PK interactions with BPH medications and dolutegravir, raltegravir, rilpivirine, or the investigational agent doravirine do not appear to exist. Clinicians working with HIV-infected individuals need to recognize the potential for interactions involving BPH and ARV treatments to ensure effective and safe drug therapy use.Keywords
This publication has 50 references indexed in Scilit:
- nullPhilosophy Study, 2016
- A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasiaExpert Opinion on Investigational Drugs, 2015
- Managing drug interactions in HIV-infected adults with comorbid illnessCanadian Medical Association Journal, 2014
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and CanadaPLOS ONE, 2013
- Association of Age With Polypharmacy and Risk of Drug Interactions With Antiretroviral Medications in HIV-Positive PatientsAnnals of Pharmacotherapy, 2013
- EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic ObstructionEuropean Urology, 2013
- Update on AUA Guideline on the Management of Benign Prostatic HyperplasiaJournal of Urology, 2011
- Established Medical Therapy for Benign Prostatic HyperplasiaUrologic Clinics of North America, 2009
- Are All Alpha-Blockers Created the Same?European Urology, 2006
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998